Clinical Trial

Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this Phase 2 study, we will conduct an efficacy and safety study of the combination of investigational drug BMX-001, with short-course radiotherapy (SCRT) or long-course chemoradiotherapy (LCCRT) as part of total neoadjuvant therapy in newly diagnosed rectal adenocarcinoma (RAC) patients.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-02-14; most recent amendment 2025-08-02.
Status change: Active, Not Recruiting → Recruiting 2023-08-05
Status change: Not Yet Recruiting → Active, Not Recruiting 2022-11-21
Trial Details
NCT Number NCT05254327
Lead Sponsor University of Nebraska
Collaborators: BioMimetix JV, LLC
Conditions Rectal Cancer
Enrollment 118 participants
Start Date 2022-08-15
Primary Completion 2027-05 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2025-08-07